Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

Inclusion Criteria

• •1. Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent.
• •2. Aged 18-75 years (inclusive).
• •3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• •4. Histologically confirmed B-cell lymphoma that expresses at least one of CD19/CD20/CD22.
• •5. At least one measurable tumor lesion determined according to Lugano 2014 criteria.
• •6. Response to prior therapy is consistent with one of the following:
• •1. Primary refractory: it means that the best response to first-line therapy (at least 2 cycles) is PD, or best response to first-line therapy (at least 4 cycles) is SD but the duration is less than 6 months, which is considered to be PD;
• •2. Relapsed or refractory after 2 or more lines of therapy. Refractory is defined that best respond to the most recent treatment regimen (at least 2 cycles) is PD, or best response to the most recent treatment regimen (at least 4 cycles) is SD but the duration is less than 6 months, which is considered to be PD;
• •3. Progression or relapse within 12 months after hematopoietic stem cell transplantation; if salvage therapy is applied after transplantation, the patient must be unresponsive or relapsed to the last line of therapy;
• •7. Life expectancy≥ 3 months
• •8. Clinical laboratory values meet screening visit criteria
• •9. Adequate organ function;